Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6 enzymes

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1350-1357

  Ahmad, Shiekh Tanveer ^a   Arjumand, Wani ^a   Seth, Amlesh ^b   Nafees, Sana ^a   Rashid, Summya ^a   Ali, Nemat ^a   Hamiza, Oday O ^a   Sultana, Sarwat ^a  

^a HAMDARD UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

AJCC cancer stage; CYP1A1; CYP2D6; Fuhrman's grade; Renal cell carcinoma; Xenobiotic metabolizing enzyme

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2D6;

ADULT; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AJCC CANCER STAGE; CYP1A1; CYP2D6; FUHRMAN'S GRADE; RENAL CELL CARCINOMA; XENOBIOTIC METABOLIZING ENZYME;

CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; METABOLIC DETOXICATION, PHASE I; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; XENOBIOTICS;

EID: 84884675890     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.12.009     Document Type: Article

References (26)

1. Ljungberg B., Campbell S.C., Cho H.Y., et al. The epidemiology of renal cell carcinoma. Eur Urol 2011, 60:615-621.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Longuemaux S., Deloménie C., Gallou C., et al. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma. Cancer Res 1999, 59:2903-2908.
4. Luo Y., Chen H., Khan M.A., et al. Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, GSTT1, and gastric carcinoma susceptibility. Tumor Biol 2011, 32:215-222.
5. Larsen J.E., Colosimo M.L., Yang I.A., et al. Risk of non-small-cell lung cancer and the cytochrome p4501a1 ile462val polymorphism. Cancer Causes Control 2005, 16:579-585.
6. Agúndez J.A.G. Cytochrome p450 gene polymorphism and cancer. Current drug metabolism 2004, 5:211-224.
7. Crofts F., Taioll E., Trachman J., et al. Functional significance of different human cyplal genotypes. Carcinogenesis 1994, 15:2961-2963.
8. Yokoi T., Kamataki T. Genetic polymorphism of drug metabolizing enzymes: New mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm Res 1998, 15:517-524.
9. Greene F.L. AJCC cancer staging handbook: From the AJCC cancer staging manual 2002, Springer Verlag, New York.
10. Chan D.K.Y., Mellick G.D., Buchanan D.D., et al. Lack of association between CYP1A1 polymorphism and Parkinson's disease in a Chinese population. J Neural Transmission 2002, 109:35-39.
11. Caporaso N., Goldstein A. Cancer genes: Single and susceptibility-exposing the difference. Pharmacogenetics and Genomics 1995, 5:59.
12. Vineis P., Bartsch H., Caporaso N., et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 1994, 369:154-156.
13. Vineis P. Molecular epidemiology: Low dose carcinogens and genetic susceptibility. Int J Cancer 1997, 71:1-3.
14. Androutsopoulos V., Tsatsakis A., Spandidos D. Cytochrome p450 CYP1A1: Wider roles in cancer progression and prevention. BMC Cancer 2009, 9:187.
15. Hayashi S., Watanabe J., Nakachi K., et al. Genetic linkage of lung cancer-associated mspi polymorphisms with amino acid replacement in the heme binding region of the human cytochrome p450ia1 gene. J Biochem 1991, 110:407-411.
16. Yadav C.S., Bajpai M., Kumar V., et al. Polymorphism in CYP1A1, GSTM1, GSTT1 genes and organochlorine pesticides in the etiology of hypospadias. Hum Exp Toxicol 2011, 78:902-907.
17. Sergentanis T.N., Economopoulos K.P. Four polymorphisms in cytochrome p450 1a1 (CYP1A1) gene and breast cancer risk: A meta-analysis. Breast Cancer Res Treatment 2010, 122:459-469.
18. Rintala S., Tammela T.L.J., Tuimala R. Cyp1A1 activity in renal cell carcinoma and in adjacent normal renal tissue. Urol Res 1998, 26:117-121.
19. Kiss I., OrsS Z., Gombos K., et al. Association between allelic polymorphisms of metabolizing enzymes (CY1A1, CYP1A2, CYP2E1, MEH) and occurrence of colorectal cancer in Hungary. Anticancer Res 2007, 27:2931-2937.
20. Sachse C., Smith G., Wilkie M.J.V., et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 2002, 23:1839-1849.
21. Pereira Serafim P.V., Cotrim Guerreiro da Silva I.D., Manoukias Forones N. Relationship between genetic polymorphism of CYP1A1 at codon 462 (ile462val) in colorectal cancer. Int J Biol Markers 2008, 23:18-23.
22. Tefre T., Ryberg D., Haugen A., et al. Human CYP1A1 (cytochrome p(1)450) gene: Lack of association between the msp i restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991, 1:20-25.
23. Ophuis M.B.O., Lieshout E.M.M., Roelofs H.M.J., et al. Glutathione s transferase m1 and t1 and cytochrome p4501a1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer 1998, 82:936-943.
24. Sachse C., Brockmöller J., Bauer S., et al. Cytochrome p450 2d6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am J Human Genet 1997, 60:284-295.
25. Thuerauf N., Lunkenheimer J. The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants. Eur Arch Psychiatry Clin Neurosci 2006, 256:287-293.
26. Yan Z., Wu Y.M., Wu Y.J. [CYP2D6 10 Polymorphisms and lung cancer susceptibility]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2008, 30:564-568.